Recursion Pharmaceuticals

Recursion Pharmaceuticals Financing Cash Flow

The Net Financing Cash Flow of Recursion Pharmaceuticals (RXRX) as of Oct 27, 2026 is 521.53 M USD. In the previous year, Net Financing Cash Flow was 304.12 M USD — a change of 71.49% (higher).

Financing Cash Flow

521.53 MUSD

YoY

71.49%

Last updated:

Net Financing Cash Flow of Recursion Pharmaceuticals is 2025 521.53 M USD. Net Financing Cash Flow of Recursion Pharmaceuticals was 2024 304.12 M USD. It decreases by 71.49% higher compared to the previous year.

The Recursion Pharmaceuticals Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2019
120.41 M USD
Jan 1, 2020
246.14 M USD
Jan 1, 2021
458.54 M USD
Jan 1, 2022
154.35 M USD
Jan 1, 2023
140.13 M USD
Jan 1, 2024
304.12 M USD
Jan 1, 2025
521.53 M USD
The Recursion Pharmaceuticals Financing Cash Flow history
YEARFinancing Cash FlowYoY
521.53 MUSD+71.49%
304.12 MUSD+117.02%
140.13 MUSD-9.21%
154.35 MUSD-66.34%
458.54 MUSD+86.30%
246.14 MUSD+104.41%
120.41 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Net Financing Cash Flow of Recursion Pharmaceuticals is 521.53 M USD in 2025.

Net Financing Cash Flow of Recursion Pharmaceuticals changed from 304.12 M USD to 521.53 M USD, representing a 71.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals